ABSTRACT
BACKGROUND:
There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases in Latin America.
OBJECTIVE:
To describe the first observational real-world experience with vedolizumab in Latin American inflammatory bowel diseases patients.
METHODS:
Retrospective observational multicentric study of patients with Crohn’s disease (CD) and ulcerative colitis (UC) who used vedolizumab at any phase of their treatment. Clinical remission and response (according to Harvey-Bradshaw index for CD and Mayo score for UC), mucosal healing, need for surgery and adverse events were evaluated.
RESULTS:
A total of 90 patients were included (52 with CD and 38 with UC), the majority with previous exposure to anti-TNF agents (88.46% in CD and 76.31% in UC). In CD (as observed analysis) remission rates at weeks 12, 26 and 52 were 42.89% (21/49), 61.9% (26/42) and 46.15% (12/26), respectively. In UC, remission rates at weeks 12, 26 and 52 were 28.94% (11/38), 36.66% (11/30) and 41.17% (7/17). Mucosal healing rates were 36.11% in CD and 43.4% in UC. During the study period, 7/52 CD patients underwent major abdominal surgery and 4/38 UC patients needed colectomy.
CONCLUSION:
Vedolizumab was effective in induction and maintenance of clinical response and remission in CD and UC, with no new safety signs.
HEADINGS:
Crohn disease; Ulcerative colitis; Inflammatory bowel diseases; Integrins; Monoclonal antibodies
Thumbnail
Thumbnail
Thumbnail
Thumbnail
